Equipo ISGlobal - Título

Equipo ISGlobal

Silvia de Sanjosé

Silvia de Sanjosé

Investigadora asociada Infecciones Víricas y Bacterianas

Dr. Silvia de Sanjosé is an MD, PhD with over 30 years of expertise in epidemiology of HPV and related cancers. She served as the President of the International Papillomavirus Society during 2015-2018 and has been Co-Chair of the Cape Town, Sydney and Barcelona (virtual) conferences of the IPVS. 

She has experience in large international studies involving HPV worldwide  genotyping and has been involved in the development of HPV based screening guidelines for cervical cancer in Spain and in Catalonia. 

She has previously worked at the International Agency for Research on Cancer, and at the Catalan Institute of Oncology. Currently serving as Consultant for US NCI. Dr. de Sanjosé leads teams working to evaluate HPV genotype information and the use of artificial intelligence applied to cervical images. She is also involved in studies providing an insight on the association between HPV and HIV in cervical carcinogenesis applied to screening strategies. She is an affiliated professor at the Department of Epidemiology,  University of Washington. She has over 470 peer reviewed mansucripts.

Líneas de investigación

  • Screening for cervical cancer in low-resource settings.
  • Impact of human immunodeficiency virus in cervical carcinogenesis.
  • Artificial inteligence applied to cervical images in women with human papillomavirus.
  • Policy issues in COVID-19 and SARS-2-CoV.

Principales publicaciones

  • Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4. PMID: 31812369; PMCID: PMC7025157.
  • Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Jul;4(7):e453-63. doi: 10.1016/S2214-109X(16)30099-7. Erratum in: Lancet Glob Health. 2017 Jul;5(7):e662. PMID: 27340003.
  • de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007 Jul;7(7):453-9. doi: 10.1016/S1473-3099(07)70158-5. PMID: 17597569.
  • de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15. PMID: 20952254.
  • Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P; ART and HPV Review Group. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018 Jan;5(1):e45-e58. doi: 10.1016/S2352-3018(17)30149-2. Epub 2017 Oct 26. PMID: 29107561; PMCID: PMC5757426.
Publicador de contenidos